Advances in the Diagnosis and Treatment of Leptomeningeal Disease.
Akanksha SharmaJustin T LowPriya U KumthekarPublished in: Current neurology and neuroscience reports (2022)
Improved molecular diagnostic tools are in development to enable more sensitive detection of LMD, including circulating tumor cells and circulating tumor DNA. The use of targeted and CNS-penetrant therapeutics has shown survival improvements with tyrosine kinase inhibitors, antibody-drug conjugates, and select chemotherapy. However, these studies have primarily been phase I/II and retrospective analyses. There remains a dearth of clinical trials that include LMD patients. The combination of patient-specific molecular information and novel therapeutic approaches holds significant promise for improving outcomes in patients with LMD.
Keyphrases
- circulating tumor
- circulating tumor cells
- sensitive detection
- cell free
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- quantum dots
- single molecule
- small molecule
- peritoneal dialysis
- blood brain barrier
- small cell lung cancer
- squamous cell carcinoma
- type diabetes
- randomized controlled trial
- healthcare
- locally advanced
- adipose tissue
- machine learning
- cerebrospinal fluid
- insulin resistance
- phase ii
- phase iii
- open label